Bristol-Myers Squibb Co (BMY) Holdings Cut by Cypress Asset Management Inc. TX

Cypress Asset Management Inc. TX lowered its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.2% in the third quarter, HoldingsChannel.com reports. The firm owned 25,550 shares of the biopharmaceutical company’s stock after selling 2,595 shares during the period. Cypress Asset Management Inc. TX’s holdings in Bristol-Myers Squibb were worth $1,586,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in BMY. Raymond James Financial Services Advisors Inc. boosted its position in shares of Bristol-Myers Squibb by 2.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock valued at $22,827,000 after acquiring an additional 10,456 shares during the period. Toronto Dominion Bank boosted its position in shares of Bristol-Myers Squibb by 19.1% in the second quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock valued at $58,813,000 after acquiring an additional 170,360 shares during the period. Aperio Group LLC boosted its position in shares of Bristol-Myers Squibb by 9.9% in the third quarter. Aperio Group LLC now owns 928,404 shares of the biopharmaceutical company’s stock valued at $57,635,000 after acquiring an additional 83,708 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of Bristol-Myers Squibb by 1.9% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock valued at $6,830,000 after acquiring an additional 2,323 shares during the period. Finally, Integrated Investment Consultants LLC boosted its position in shares of Bristol-Myers Squibb by 1,748.8% in the second quarter. Integrated Investment Consultants LLC now owns 63,468 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 60,035 shares during the period. 72.32% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE BMY traded down $1.69 during trading hours on Friday, reaching $54.29. The stock had a trading volume of 1,331,074 shares, compared to its average volume of 6,380,676. The company has a current ratio of 1.40, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $96.27 billion, a price-to-earnings ratio of 18.26, a PEG ratio of 1.58 and a beta of 0.98. Bristol-Myers Squibb Co has a twelve month low of $49.96 and a twelve month high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. The business had revenue of $5.70 billion during the quarter, compared to analyst estimates of $5.48 billion. Bristol-Myers Squibb had a return on equity of 42.58% and a net margin of 1.74%. Bristol-Myers Squibb’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.74 earnings per share. On average, research analysts anticipate that Bristol-Myers Squibb Co will post 3.64 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Investors of record on Friday, October 5th will be paid a $0.40 dividend. The ex-dividend date is Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.95%. Bristol-Myers Squibb’s payout ratio is 53.16%.

Several equities research analysts have recently weighed in on BMY shares. SunTrust Banks reissued a “buy” rating and issued a $67.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, July 31st. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Friday, October 5th. Barclays increased their price objective on Bristol-Myers Squibb from $55.00 to $58.00 and gave the company an “equal weight” rating in a research report on Friday, October 12th. BMO Capital Markets reissued a “hold” rating on shares of Bristol-Myers Squibb in a research report on Sunday, July 22nd. Finally, Jefferies Financial Group set a $58.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Sunday, July 15th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $63.13.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Featured Article: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply